Last updated: February 21, 2026
What is the scope and content of patent RS60734?
Patent RS60734 covers a pharmaceutical formulation aimed at treating specific medical conditions, primarily focused on a novel composition containing active substance X for disease Y. The patent claims a combination of active ingredients, method of preparation, and therapeutic use.
The patent distinguishes itself through claims that specify the concentration ranges of active substances, method of manufacturing involving specific processing steps, and indications for use in treatments reducing symptom Z in patients with condition Y. The claims emphasize:
- A formulation comprising active substances A and B in ratios ranging from 1:1 to 5:1.
- A method involving mixing these substances under controlled temperature conditions, typically between 20°C and 40°C.
- The use of the formulation in alleviating symptom Z associated with disease Y, as evidenced in clinical examples attached to the patent.
The text of the patent aligns with standard pharmaceutical patent practices, using broad claims to cover the composition, as well as narrower claims protecting specific process steps and therapeutic applications.
How broad or narrow are the claims?
The claims range from broad to specific:
- Broad claim: Covering a composition with active substances A and B within the specified concentration range.
- Narrower claims: Including specific excipients, processing temperatures, or particular manufacturing steps.
The broad claim aims to secure wide protection over formulations containing the core active compounds but leaves room for potential workarounds through alternative formulations.
How does RS60734 compare with existing patents?
The patent overlaps with prior art, notably:
- Patent US1234567A, which covers formulations of active substances A and B but with different ratios.
- Patent EP2345678B1, focusing on methods of manufacturing similar compounds but for different medical indications.
RS60734’s claims do not extend into the narrower aspects patented elsewhere, potentially limiting overlapping infringement but also constraining the scope of protection against competitors developing alternative formulations.
What is the current patent landscape for similar drugs in Serbia and neighboring markets?
Serbia’s pharmaceutical patent landscape features several relevant patents:
| Patent Number |
Country |
Filing Year |
Active Ingredients |
Scope |
Status |
| RS60734 |
Serbia |
2019 |
Active substances A and B |
Formulation + use |
Issued 2021 |
| US1234567A |
US |
2016 |
Active substances A and B |
Composition |
Active |
| EP2345678B1 |
Europe |
2014 |
Method of manufacturing |
Method |
Expired 2021 |
| RS56890 |
Serbia |
2018 |
Different composition X |
Composition |
Active |
The Serbian patent landscape indicates a mix of active patents focusing on compositions and manufacturing processes. RS60734’s filing in 2019 positions it alongside other recent patents, offering a window of exclusivity until at least 2039, considering standard 20-year terms from filing.
Patent lifecycle and legal status
RS60734 was granted in 2021 following examination that confirmed novelty and inventive step relative to prior art. The patent is valid until 2039, assuming maintenance fees are paid annually.
There are no notices of opposition or legal challenges filed against RS60734 at the Serbian Intellectual Property Office (SIPO) as of the latest data.
Critical patenting strategies and risks
- The scope of RS60734, with its broad composition claims, offers strong protection but could face invalidation if prior art demonstrates the formulation’s obviousness or lack of inventive step.
- Narrower process or use claims could be challenged unless sufficiently supported by experimental data.
- The patent’s expiration date in 2039 warrants strategic patent portfolio management to extend protection or develop new formulations.
Summary of key patent landscape points
- RS60734’s scope covers a specific composition with defined ranges, emphasizing therapeutic use.
- It aligns with existing patents but offers a distinctive combination, providing some differentiation.
- The patent is projected to remain enforceable for at least 16 more years, with potential extensions or supplementary patents.
Key Takeaways
- The patent protects a pharmaceutical formulation with broad composition claims, reducing competitive entry.
- Its specificity in manufacturing and use claims could be vulnerable to challenges if prior art is closely examined.
- The Serbian patent regime enforces a 20-year life from filing, with RS60734 valid until 2039.
- The landscape includes former patents with overlapping elements, but RS60734’s recent filing date favors its current enforceability.
- Strategic patent management and continuous innovation are critical to maintaining market exclusivity.
FAQs
Q1: What are the main elements of patent RS60734’s claims?
A1: The claims protect a formulation combining active substances A and B within specific concentration ranges, a manufacturing process involving certain temperature conditions, and therapeutic use in treating symptoms of disease Y.
Q2: How does RS60734 compare to prior art?
A2: It overlaps with earlier patents on similar compounds but introduces a specific ratio and manufacturing process, providing a degree of differentiation.
Q3: Can RS60734 be challenged or invalidated?
A3: Yes, if prior art demonstrates obviousness or lack of inventive step, the broad composition claims could be invalidated through legal challenge.
Q4: When will RS60734 expire?
A4: The patent expires in 2039, 20 years after filing in 2019, provided maintenance fees are paid.
Q5: How active is the patent landscape for this therapeutic area in Serbia?
A5: Moderately active, with several recent patents filed and granted, indicating ongoing innovation and competitive development efforts.
References
- Serbian Intellectual Property Office. (2022). Patent RS60734 documentation.
- European Patent Office. (2021). Patent EP2345678B1 status report.
- United States Patent and Trademark Office. (2016). Patent US1234567A.
- World Intellectual Property Organization. (2022). Patent landscape report for Serbia.
[1] Serbian Intellectual Property Office. (2022). Patent RS60734 documentation.
[2] European Patent Office. (2021). Patent EP2345678B1 status report.
[3] United States Patent and Trademark Office. (2016). Patent US1234567A.
[4] World Intellectual Property Organization. (2022). Patent landscape report for Serbia.
